Today, PatientView has published their annual survey ‘The Corporate Reputation of Pharma. Based on feedback from 1,330 patient groups, 46 pharma companies were surveyed for their corporate reputation based on 12 different indicators. Overall, Lundbeck made the top tier and specifically excelled in patient centricity, patient information, integrity and quality of patient group relationships.
Read the release from PatientView
Collaboration with patient groups is pivotal
“There is a lot to be proud of in this global survey, which recognizes our extensive efforts to engage with patient groups on a local and global level. The survey underlines our engagement in mutually meaningful relationships for the patient groups and Lundbeck. Strong partnerships with patient groups all around the world is key in our commitment to people living with psychiatric and neurological disorders,” says Interim CEO & CFO, Anders Götzsche.
Patient groups’ loyalty to Lundbeck is best in class
For the first time, PatientView assessed the patient groups loyalty to the companies, measured by the Net Promotor Score. A score for how likely they are to promote a company. Lundbeck excelled on this parameter and came out best in class with the highest Net Promoter Score among the 46 pharma companies.
Figure: Calculation of the Net Promotor Score
Snapshots of Lundbeck’s ranking and profile of the respondents
|In 2017, the twelve indicators of corporate reputation were:
|1. Patient centricity
||5i. Transparency: pricing [new]
||7. Quality of relationships with patient groups
|2. Patient information
||5ii. Transparency: clinical-trial data [new]
||8. 'Beyond the pill' [new]
|3. Patient safety
||5iii. Transparency: funding of stakeholders
||9i. Engaging patients in research [new]
|4. High-quality products
||9ii. Engaging patients in development [new]